Contribution of vascular risk factors to the progression in Alzheimer disease

Archives of Neurology

Volumn 66, Issue 3, 2009, Pages 343-348

  Helzner, Elizabeth P ^a   Luchsinger, José A ^a,b   Scarmeas, Nikolaos ^a,b   Cosentino, Stephanie ^a   Brickman, Adam M ^b   Glymour, M Maria ^b   Stern, Yaakov ^a,b,c  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ALZHEIMER DISEASE; ANAMNESIS; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COGNITION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; FEMALE; FOLLOW UP; HEART DISEASE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; PRIORITY JOURNAL; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; CEREBROVASCULAR DISORDERS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COGNITION; COHORT STUDIES; COMMUNITY HEALTH PLANNING; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 62449242294     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.66.3.343     Document Type: Article

References (37)

1. Barba R, Martínez-Espinosa S, Rodríguez-García E, Pondal M, Vivancos J, Del Ser T. Poststroke dementia: clinical features and risk factors. Stroke. 2000;31(7):1494-1501.
2. DeCarli C. The role of cerebrovascular disease in dementia. Neurologist. 2003;9(3):123-136.
3. Korczyn AD. The underdiagnosis of the vascular contribution to dementia. J Neurol Sci. 2005;229-230:3-6.
4. Luchsinger JA, Mayeux R. Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep. 2004;6(4):261-266.
5. Honig LS, Tang MX, Albert S, et al. Stroke and the risk of Alzheimer disease [published correction appears in Arch Neurol. 2004;61(3):368]. Arch Neurol. 2003;60(12):1707-1712.
6. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004;63(7):1187-1192.
7. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001;154(7):635-641.
8. Merchant C, Tang MX, Albert S, Manly J, Stern Y, Mayeux R. The influence of smoking on the risk of Alzheimer's disease. Neurology. 1999;52(7):1408-1412.
9. Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology. 2002;58(8):1175-1181.
10. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol. 2004;61(5):705-714.
11. Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA. 1999;282(3):254-260.
12. Breteler MM. Vascular risk factors for Alzheimer's disease. Neurobiol Aging. 2000;21(2):153-160.
13. Regan C, Katona C, Walker Z, Hooper J, Donovan J, Livingston G. Relationship of vascular risk to the progression of Alzheimer disease. Neurology. 2006;67(8):1357-1362.
14. Mielke MM, Rosenberg PB, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology. 2007;69(19):1850-1858.
15. Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population: development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol. 1992;49(5):453-460.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
17. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974;24(11):1019-1025.
18. Benton A. The Visual Retention Test. New York, NY: Psychological Corp; 1955.
19. Wechsler D. Wechsler Adult Intelligence Scale Revised. New York, NY: Psychological Corp; 1981.
20. Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellak LKT, ed. Geriatric Psychiatry. New York, NY: Grune & Stratton; 1976:77-121.
21. Rosen WG. The Rosen Drawing Test. Bronx, NY: Veterans Administration Medical Center; 1981.
22. Goodglass HKD. The Assessment of Aphasia and Related Disorders. 2nd ed. Philadelphia, PA: Lea & Febiger; 1983.
23. Benton ALHK, Sivan AB. Manual for the Multilingual Aphasia Examination. 3rd ed. Iowa City, IA: AJA Associates, Inc; 1994.
24. Scarmeas N, Albert SM, Manly JJ, Stern Y. Education and rates of cognitive decline in incident Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2006;77(3):308-316.
25. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 1976;54(5):541-553.
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
27. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31(3):545-548.
28. Hanley JA, Negassa A, Edwardes MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157(4):364-375.
29. Morris J. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;44(10):2412-2414.
30. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA. 1997;277(10):813-817.
31. Jellinger KA. The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol. 2007;113(4):349-388.
32. Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR. Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology. 2004;62(10):1869-1871.
33. Masse I, Bordet R, Deplanque D, et al. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005;76(12):1624-1629.
34. Lesort M, Johnson GV. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience. 2000;99(2):305-316.
35. Peila R, Rodriguez BL, Launer LJ; Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 2002;51(4):1256-1262.
36. Cosentino S, Scarmeas N, Helzner E, et al. APOE epsilon4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology. 2008;70(19, pt 2):1842-1849.
37. Kuller LH, Lopez OL, Jagust WJ, et al. Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology. 2005;64(9):1548-1552.